Carcinoid TumorNCT07317713
A Two-decade Mortality Risk Analysis of Gastrointestinal Carcinoid Neoplasms: an Updated SEER-based Study 2000-2022
An observational study of Carcinoid Tumor, run by Suez Canal University.
Trial summary
Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course with the sites are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). This study focus on the mortality risk analysis for GI carcinoids due to data insufficiency in the literature. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Carcinoid Tumor
- How many people
- 93,481 participants
- Where
- No sites listed yet
- Study dates
- 1 Dec 2000to 30 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The inclusion criteria involved all patients with primary malignant GI carcinoid tumor diagnosed between 2000 and 2022 with sequence number 0 or 1. Sequence 0 indicated the patient had only one cancer record while sequence 1 indicated the patient may had developed many cancer records following the first one. In addition, the tumors were restricted to malignant behavior codes (ICD-O-3 Code 3).
Who may be able to join
- patients diagnosed with gastrointestinal carcinoid tumor
- from 2000-2022
- histologically confirmed
Who cannot join
- death certificate only and autopsy only patients
- patients with unknown age data.
About this study
Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course with the sites are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). This study focus on the mortality risk analysis for GI carcinoids due to data insufficiency in the literature.
Read the detailed description
Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course with the sites are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). This study focus on the mortality risk analysis for GI carcinoids due to data insufficiency in the literature. This is a retrospective cohort study based on the Surveillance, Epidemiology, and End Results (SEER) database using SEER*Stat software covering approximately 28% of the U.S. The inclusion criteria involved all patients with primary malignant GI carcinoid tumor diagnosed between 2000 and 2021 with sequence number 0 or 1. Sequence 0 indicated the patient had only one cancer record while sequence 1 indicated the patient may had developed many cancer records following the first one. In addition, the tumors were restricted to malignant behavior codes (ICD-O-3 Code 3). We used SEER*Stat software (version 9.0.42.0) to conduct data extraction and statistical analysis. We used the MP-SIR session to calculate the SMR as Observed/Expected (O/E) with a 95% confidence interval (CI) and the excess risk (ER) was per 10,000. Statistical significance was achieved at 0.05. With further analysis, we compared cancer as a cause of death (COD) to other non-cancer COD across different time intervals and primary sites among GI carcinoid tumour.
- Conditions
- Carcinoid Tumor
- Medical subject headings
- Carcinoid Tumor
What is being measured
The primary outcome is the main question the study is designed to answer.
The standardized mortality ratio of GI carcinoid tumors
SEER*Stat software (version 9.0.42.0) was used to conduct data extraction and statistical analysis. The MP-SIR session was used to calculate the SMR as Observed/Expected (O/E) with a 95% confidence interval (CI) and the excess risk was per 10,000. Statistical significance was achieved at 0.05. With further analysis, we compared cancer as a cause of death to other non-cancer causes of death across different time intervals and primary sites among GI carcinoid tumour.
Measured: 2000-2022
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2026
- Study start1 Dec 2000
- Primary completion30 Dec 2022
- Study completion30 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Carcinoid TumorStudies of the same condition, open and under way.
- More trials run by Suez Canal UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 93,481 participants (actual)
Sponsor and investigators
- Lead sponsor
- Suez Canal University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, asmaa salama ibrahim, Suez Canal University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07317713
- Sponsor's protocol ID
- A277
- Status last verified
- Dec 2025
- First submitted
- 19 Dec 2025
- Last updated
- 5 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Two-decade Mortality Risk Analysis of Gastrointestinal Carcinoid Neoplasms: an Updated SEER-based Study 2000-2022
- ClinicalTrials.gov ID
- NCT07317713
- Acronym / sponsor ID
- A277
- Conditions
- Carcinoid Tumor
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 93,481 participants (actual)
- Lead sponsor
- Suez Canal UniversityUniversity, hospital or other
- Study start
- 1 Dec 2000 (actual)
- Primary completion
- 30 Dec 2022 (actual)
- Study completion
- 30 Dec 2022 (actual)
- First posted
- 5 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course with the sites are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). This study focus on the mortality risk analysis for GI carcinoids due to data insufficiency in the literature.
Detailed description
Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course with the sites are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). This study focus on the mortality risk analysis for GI carcinoids due to data insufficiency in the literature. This is a retrospective cohort study based on the Surveillance, Epidemiology, and End Results (SEER) database using SEER*Stat software covering approximately 28% of the U.S. The inclusion criteria involved all patients with primary malignant GI carcinoid tumor diagnosed between 2000 and 2021 with sequence number 0 or 1. Sequence 0 indicated the patient had only one cancer record while sequence 1 indicated the patient may had developed many cancer records following the first one. In addition, the tumors were restricted to malignant behavior codes (ICD-O-3 Code 3). We used SEER*Stat software (version 9.0.42.0) to conduct data extraction and statistical analysis. We used the MP-SIR session to calculate the SMR as Observed/Expected (O/E) with a 95% confidence interval (CI) and the excess risk (ER) was per 10,000. Statistical significance was achieved at 0.05. With further analysis, we compared cancer as a cause of death (COD) to other non-cancer COD across different time intervals and primary sites among GI carcinoid tumour.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The inclusion criteria involved all patients with primary malignant GI carcinoid tumor diagnosed between 2000 and 2022 with sequence number 0 or 1. Sequence 0 indicated the patient had only one cancer record while sequence 1 indicated the patient may had developed many cancer records following the first one. In addition, the tumors were restricted to malignant behavior codes (ICD-O-3 Code 3).
Key inclusion criteria (3 listed)
- patients diagnosed with gastrointestinal carcinoid tumor
- from 2000-2022
- histologically confirmed
Key exclusion criteria (2 listed)
- death certificate only and autopsy only patients
- patients with unknown age data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The standardized mortality ratio of GI carcinoid tumors
Time frame: 2000-2022
SEER*Stat software (version 9.0.42.0) was used to conduct data extraction and statistical analysis. The MP-SIR session was used to calculate the SMR as Observed/Expected (O/E) with a 95% confidence interval (CI) and the excess risk was per 10,000. Statistical significance was achieved at 0.05. With further analysis, we compared cancer as a cause of death to other non-cancer causes of death across different time intervals and primary sites among GI carcinoid tumour.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Carcinoid Tumor
RecruitingPhase 3
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingObservational study
Natural History of Familial Carcinoid Tumor
Carcinoid
RecruitingObservational study
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Esophageal Cancer, Head and Neck Cancer
RecruitingPhase 1
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Carcinoid Tumor, run by Suez Canal University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The standardized mortality ratio of GI carcinoid tumors (time frame: 2000-2022). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2026.